Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. Dr. Russo has over 20 years experience in cannabinoid-based pharmaceutical development. From 2003-2014, he served as senior medical advisor, medical monitor and study physician to GW Pharmaceuticals for Phase I-III clinical trials of first-to-market cannabinoid-based prescription drugs Sativex® for cancer pain and Epidiolex® for intractable epilepsy. Dr. Russo has served in 23 clinical trials in the areas of multiple sclerosis (MS), epilepsy, amyotrophic lateral sclerosis (ALS), autism, neuropathic pain and cancer pain and has authored over 50 peer-reviewed scientific publications and seven books. He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines.